The complexity of breast cancer has led to the development of specialized treatment regimens that are dependent on tumor stage, grade, and the presence or absence of hormone receptors (HR; estrogen receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)). This evidence concerns the gene ERBB2 and breast carcinoma.